1986
DOI: 10.1016/0022-510x(86)90006-7
|View full text |Cite
|
Sign up to set email alerts
|

Successful treatment of murine muscular dystrophy with the protease inhibitor bestatin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
4
0

Year Published

1988
1988
2007
2007

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 23 publications
0
4
0
Order By: Relevance
“…In the dy/dy mouse, the muscle initially appears normal, with normal fiber-type differentiation up to 2 wk of age, when the necrotic process starts. After 1 mo of age, there is marked variation in fiber size with necrotic and regenerating fibers (30). Interstitial fibrosis becomes evident as the disease progresses.…”
mentioning
confidence: 99%
“…In the dy/dy mouse, the muscle initially appears normal, with normal fiber-type differentiation up to 2 wk of age, when the necrotic process starts. After 1 mo of age, there is marked variation in fiber size with necrotic and regenerating fibers (30). Interstitial fibrosis becomes evident as the disease progresses.…”
mentioning
confidence: 99%
“…When we consider bestatin as a therapeutic agent for muscular dystrophies, it is important to note that bestatin has a membrane stabilizing action in addition to its previously proposed effect as a protease inhibitor. 12 The amount of bestatin that has been used for the dy/dy mice is 0.4mg/day,12 which corresponds to half of our dose for the mdx mice. The dosage of lOOmg/kg body weight/day used in our study was a relatively large amount.…”
Section: Discussionmentioning
confidence: 99%
“…It can also enhance the G-and GM-CSF-induced colony formation to modulate the proliferation and differentiation of human bone marrow cells [10,11]. Because of these significant therapeutic activities, bestatin has been studied as a therapeutic drug for cancer, resistant infection, muscular dystrophy [12], myelodysplastic syndrome and chronic leukemia [13].…”
Section: Introductionmentioning
confidence: 98%